Stock Events

Stock Events

Maat Pharma. 

$4.85
13
-$0.13-2.56% Thursday 13:04

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
78.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30MarExpected
Q2 2024
Q4 2024
Q2 2025
Next
-1.36
-1.26
-1.16
-1.06
Expected EPS
-1.3624316
Actual EPS
N/A

Financials

-897.34%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
6.72MRevenue
-60.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MATPF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Serve Robotics
SERV
Mkt Cap814.67M
Seres Therapeutics, Inc. focuses on microbiome therapeutics, directly competing in the same space as Maat Pharma with its microbiome restoration therapy products.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. is involved in gene therapy, which includes treatments that could overlap with Maat Pharma's microbiome-based approaches for certain diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated works on creating new therapies for treating cystic fibrosis and other serious diseases, potentially competing in indications Maat Pharma targets with its microbiome solutions.
Synlogic
SYBX
Mkt Cap19.77M
Synlogic, Inc. is pioneering synthetic biotic medicines, directly competing in the innovative treatment space, including microbiome engineering, similar to Maat Pharma's focus.
Forte Biosciences
FBRX
Mkt Cap160.88M
Fortress Biotech, Inc. is involved in the development of novel pharmaceutical therapies, including areas that might overlap with Maat Pharma's microbiome therapeutic applications.
Evelo Biosciences
EVLO
Mkt Cap9,491
Evelo Biosciences, Inc. focuses on developing microbiome-based therapies, making it a direct competitor in the field of microbiome science like Maat Pharma.
Seres Therapeutics
MCRB
Mkt Cap140.95M
Seres Therapeutics, Inc. (duplicate entry for SERV, focusing on microbiome therapeutics, directly competing with Maat Pharma in microbiome restoration therapy products).
Ardelyx
ARDX
Mkt Cap1.47B
Ardelyx, Inc. develops drugs for gastrointestinal and cardio-renal diseases, areas where microbiome therapies developed by Maat Pharma could be applied.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals Ltd. works on liver diseases and metabolic disorders, potentially competing with Maat Pharma's microbiome-based treatments for similar conditions.

About

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
Show more...
CEO
ISIN
FR0012634822

Listings

F
DE
4RD.F
Grey Market
US
MATPF
PA
FR
MAAT.PA

0 Comments

Share your thoughts

FAQ

What is Maat Pharma. stock price today?▼
The current price of MATPF is $4.85 USD — it has decreased by -2.56% in the past 24 hours. Watch Maat Pharma. stock price performance more closely on the chart.
What is Maat Pharma. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Maat Pharma. stocks are traded under the ticker MATPF.
What is Maat Pharma. market cap?▼
Today Maat Pharma. has the market capitalization of 78.27M
When is the next Maat Pharma. earnings date?▼
Maat Pharma. is going to release the next earnings report on September 30, 2026.
What is Maat Pharma. revenue for the last year?▼
Maat Pharma. revenue for the last year amounts to 6.72M USD.
What is Maat Pharma. net income for the last year?▼
MATPF net income for the last year is -60.3M USD.
When did Maat Pharma. complete a stock split?▼
Maat Pharma. has not had any recent stock splits.